Developer docs
API playgroundTry for free, no card

Search company profiles

UbiQ

Full company profile

uuid0021dir

Namestring
UbiQ
Legal namestring
UbiQ Bio BV
Websiteurl
ubiqbio.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

UbiQ Bio BV is a privately held Dutch life-science research tools company founded in 2010 and headquartered at Amsterdam Science Park. The company develops and commercializes chemical reagents for studying the ubiquitin-proteasome system and related ubiquitin-like (Ubl) modifications. Its portfolio spans site-selectively ubiquitinated peptides, activity-based probes (including a Triple E probe architecture that sequentially targets E1-E2-E3 enzymes), di-ubiquitin chains, and assay reagents, as well as Ubl variants such as SUMO, ISG15, and NEDD8. The company's defining technical capability is total and site-selective chemical synthesis of ubiquitin conjugates, which it states can produce reagents not achievable through biological expression systems.

UbiQ serves two primary customer segments: pharmaceutical and biotechnology companies working on ubiquitin-pathway drug discovery, and academic research laboratories conducting structural biology, enzymology, and fundamental ubiquitin research. The company makes money through two streams: standardized catalogue reagents sold direct via its e-commerce storefront (typical ASP around €300-350 per 50 µg unit, pay-as-you-go billing), and quote-based custom synthesis services for tailored ubiquitinated conjugates (multi-year contractual relationships). Distribution is direct and global. UbiQ also invests in scientific visibility through conference exhibition, award sponsorship, and co-authored publications with leading academic groups at NYU, the Netherlands Cancer Institute, University of Texas Health Science Center, University of Leeds, and University of Pennsylvania, among others. The company is led by co-founder Alfred Nijkerk (CEO) and co-founder Farid El Oualid (CSO), with a small operating team and no disclosed external funding.

Short descriptiontext

UbiQ Bio BV is a Dutch specialty reagent company that chemically synthesizes site-selective ubiquitin and ubiquitin-like research tools — including activity-based probes and assay reagents — and sells them to pharmaceutical drug discovery teams and academic laboratories worldwide via catalogue e-commerce and custom synthesis services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ubiquitin research tools, activity-based probes, ubiquitinated peptides, life science reagents, deubiquitinating enzyme assays
Industry3 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Life Science Research Reagents
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Catalogue reagent sales
TypeOne Time License
Description

Sale of standardized ubiquitin research reagents including ubiquitinated peptides, activity-based probes, di-ubiquitin chains, and assay reagents through e-commerce platform.

ubiqbio.com
2Custom reagent synthesis
TypeOne Time License
Description

Custom synthesis services for producing tailored ubiquitinated conjugates and peptides not available through standard catalogue, providing specialized solutions for specific research requirements.

ubiqbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details2 tiers
1Standard catalogue reagents
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products sold in standard aliquot sizes (e.g., 50 µg) with per-unit pricing starting from €300-350 for assay reagents. Bulk sizes available at higher prices.

ubiqbio.com
2Custom synthesis services
ModelOtherBilling cadenceMulti-year contract
Notes

Custom reagent services are quote-based, pricing determined by complexity and quantity requirements.

ubiqbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

UbiQ develops, manufactures, and commercializes ubiquitin and ubiquitin-like research reagents, including ubiquitinated peptides, activity-based probes, and activity assay reagents, using proprietary site-selective chemical synthesis technology at its Amsterdam Science Park laboratory. The company offers a catalogue of standardized reagents covering ubiquitin, SUMO, ISG15, and NEDD8 variants, alongside custom synthesis services that produce tailored ubiquitinated conjugates not readily achievable through biological methods. These tools support pharmaceutical drug discovery, fundamental academic research, and structural biology studies targeting the ubiquitin-proteasome system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Tools used by many leading laboratories in the ubiquitin field worldwide
+1 more record
Product and service7 records
1Catalogue Ubiquitin and Ubiquitin-Like Reagents
CategoryUbiquitin Research Reagents
Description

Standardized catalogue of ubiquitinated peptides, activity-based probes, and activity assay reagents for ubiquitin and ubiquitin-like research, available for direct purchase. Products are manufactured at UbiQ's Amsterdam Science Park laboratory and are for laboratory research use only.

2Custom Ubiquitin Reagents Service
CategoryCustom Reagent Services
Description

Custom chemical synthesis of tailored ubiquitinated conjugates and reagents for researchers with specific requirements not met by catalogue products, using UbiQ's site-selective chemical synthesis technology.

3Custom Ubiquitinated Peptides
CategoryCustom Reagent Services
Description

Custom chemical synthesis of specific ubiquitinated peptides enabling researchers to design unique conjugates for specialized experimental needs, leveraging site-selective synthesis not achievable through biological approaches.

4UbiQ-378 - Biotin-Ahx-Ub-MTC Activity-Based Probe
CategoryActivity-Based Probes
Description

Biotin-Ahx-Ub-MTC, a new type of activity-based probe for deubiquitinating enzymes, designed for researchers studying DUB activity and ubiquitin pathway mechanisms.

5UbiQ-381 - L17ER4 Endosomolytic Peptide
CategoryDelivery Reagents
Description

L17ER4, an endosomolytic peptide reagent for intracellular delivery of ubiquitin and ubiquitin-like reagents into live cells, enabling intracellular research applications.

6UbiQ-344 - Ubiquitin (1-75)
CategoryUbiquitin Variants
Description

Ubiquitin(1-75) reagent prepared by total chemical synthesis, lacking the C-terminal Gly76 residue and therefore unable to be activated by an E1 enzyme, useful for specialized research applications.

7UbiQ-158 - His6-3C-MAP1LC3a-Dha Activity-Based Probe
CategoryActivity-Based Probes
Description

His6-3C-MAP1LC3a-Dha, an activity-based probe targeting E1-E2-E3 enzymes involved in autophagy, designed for researchers studying autophagy-related enzyme mechanisms.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership9 partners
1New York University School of Medicine
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-26
Description

Collaborative research partnership with Tony T. Huang's lab at NYU School of Medicine on deubiquitinases regulating cleavage and stability of ubiquitin-fused ribosomal proteins, resulting in publication in Molecular Cell 2025.

ubiqbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

Scientific collaboration with Niels Keijzer and team at NKI on USP1/UAF1 targeting polyubiquitinated PCNA, resulting in Nature Communications publication 2025.

3Wroclaw University of Science and Technology
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-16
Description

Collaborative partnership contributing chapter to Methods in Molecular Biology book series on ubiquitin and ISG15 deconjugase characterization.

ubiqbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-23
Description

Collaborative research partnership contributing to characterization of SARS-CoV-1 and SARS-CoV-2 papain-like protease ubiquitin and ISG15 deconjugase activity, published in Methods in Molecular Biology 2023.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-29
Description

Collaborative research on essential roles of ubiquitin proteases and ubiquitin conjugation in Leishmania parasites with Prof Jeremy Mottram's lab.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-29
Description

Collaboration with Daniel Harris and Dr Richard Burchmore on ubiquitin activating enzyme as novel therapeutic target for leishmaniasis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-29
Description

Collaboration with Dr Danny Huang and Dr Mads Gabrielson on Leishmania ubiquitin system research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-29
Description

International collaboration led by Dr Elton Zeqiraj on cryo-EM structure of human BRISC-SHMT2 complex involved in cell metabolism and immune response, published in Nature 2019.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-29
Description

Collaboration with Prof Roger Greenberg on structure of BRISC-SHMT2 complex showing metabolic regulation of immune signaling through ubiquitin pathway, published in Nature 2019.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

LifeSensors is the closest direct competitor to UbiQ. It specializes in ubiquitin, ubiquitin-like, and SUMO research reagents, activity-based probes, and enzymes, serving both academic and pharma drug-discovery customers in the UPS field.

2UBPBio
TypeDirect peer
Description

UBPBio offers ubiquitin pathway research tools including DUB activity assays, ubiquitin chains, and E3 ligase substrates. It competes head-to-head with UbiQ in catalog DUB/UPS reagents used for compound screening and target validation.

3MilliporeSigma (Merck KGaA Life Science)
TypeBroad incumbent
Description

MilliporeSigma supplies an extensive catalog of biochemicals, proteins, and research reagents, including ubiquitin and proteasome-related products. As a global broad incumbent, it competes with UbiQ across standardized research reagents.

TypeBroad incumbent
Description

Promega provides a broad portfolio of life-science reagents and assay kits, including proteasome and protease tools. As a broad incumbent, it overlaps with UbiQ in drug-discovery assay reagents used by pharma and academic researchers.

TypeEmerging player
Description

Cayman Chemical supplies biochemical research tools including UPS-related probes, inhibitors, and assay reagents. It overlaps with UbiQ in serving drug-discovery and academic customers targeting the ubiquitin pathway.

6South Bay Bio
TypeEmerging player
Description

South Bay Bio offers ubiquitin and ubiquitin-like reagents and conjugates, including di-ubiquitin chains and activity probes. As a smaller specialty provider, it competes with UbiQ in the UPS reagent niche.

TypeBroad incumbent
Description

Abcam supplies research-grade antibodies and protein reagents, including products targeting ubiquitin pathway components. It competes with UbiQ in serving the same academic and pharma research customer base.

TypeBroad incumbent
Description

CST is a major provider of antibodies and reagents for cell signaling research, including UPS-related targets. It overlaps with UbiQ in serving academic and pharma labs studying post-translational modifications.

TypeBroad incumbent
Description

Enzo supplies life-science research reagents including proteasome, DUB, and ubiquitin-related assay kits and inhibitors. It is a broad incumbent that overlaps with UbiQ in UPS drug-discovery tools.

TypeBroad incumbent
Description

Bio-Techne is a large life-science tools incumbent that supplies proteins, antibodies, and small-molecule reagents (including UPS-related tools) across pharma and academia. It competes broadly with UbiQ's reagent catalog and could enter adjacent ubiquitin specialties.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UbiQ

Life Science Research Reagentsubiqbio.com

UbiQ Bio BV is a Dutch specialty reagent company that chemically synthesizes site-selective ubiquitin and ubiquitin-like research tools — including activity-based probes and assay reagents — and sells them to pharmaceutical drug discovery teams and academic laboratories worldwide via catalogue e-commerce and custom synthesis services.

What UbiQ does

UbiQ Bio BV is a privately held Dutch life-science research tools company founded in 2010 and headquartered at Amsterdam Science Park. The company develops and commercializes chemical reagents for studying the ubiquitin-proteasome system and related ubiquitin-like (Ubl) modifications. Its portfolio spans site-selectively ubiquitinated peptides, activity-based probes (including a Triple E probe architecture that sequentially targets E1-E2-E3 enzymes), di-ubiquitin chains, and assay reagents, as well as Ubl variants such as SUMO, ISG15, and NEDD8. The company's defining technical capability is total and site-selective chemical synthesis of ubiquitin conjugates, which it states can produce reagents not achievable through biological expression systems.

UbiQ serves two primary customer segments: pharmaceutical and biotechnology companies working on ubiquitin-pathway drug discovery, and academic research laboratories conducting structural biology, enzymology, and fundamental ubiquitin research. The company makes money through two streams: standardized catalogue reagents sold direct via its e-commerce storefront (typical ASP around €300-350 per 50 µg unit, pay-as-you-go billing), and quote-based custom synthesis services for tailored ubiquitinated conjugates (multi-year contractual relationships). Distribution is direct and global. UbiQ also invests in scientific visibility through conference exhibition, award sponsorship, and co-authored publications with leading academic groups at NYU, the Netherlands Cancer Institute, University of Texas Health Science Center, University of Leeds, and University of Pennsylvania, among others. The company is led by co-founder Alfred Nijkerk (CEO) and co-founder Farid El Oualid (CSO), with a small operating team and no disclosed external funding.

UbiQ firmographics

Firmographics
Name
UbiQ
Legal name
UbiQ Bio BV
Website
https://ubiqbio.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
UbiQ Bio BV is a Dutch specialty reagent company that chemically synthesizes site-selective ubiquitin and ubiquitin-like research tools — including activity-based probes and assay reagents — and sells them to pharmaceutical drug discovery teams and academic laboratories worldwide via catalogue e-commerce and custom synthesis services.
Ownership category
akta.pro rank

UbiQ industry classification

Industry
Product category
Life Science Research Reagents
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Ubiquitin research tools
  • Activity-based probes
  • Ubiquitinated peptides
  • Life science reagents
  • Deubiquitinating enzyme assays

Where UbiQ is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

UbiQ business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Catalogue reagent sales: Sale of standardized ubiquitin research reagents including ubiquitinated peptides, activity-based probes, di-ubiquitin chains, and assay reagents through e-commerce platform.
  2. Custom reagent synthesis: Custom synthesis services for producing tailored ubiquitinated conjugates and peptides not available through standard catalogue, providing specialized solutions for specific research requirements.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard catalogue reagents
OtherMulti-year contractCustom synthesis services

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

UbiQ product offering

Product offering

Core offering

UbiQ develops, manufactures, and commercializes ubiquitin and ubiquitin-like research reagents, including ubiquitinated peptides, activity-based probes, and activity assay reagents, using proprietary site-selective chemical synthesis technology at its Amsterdam Science Park laboratory. The company offers a catalogue of standardized reagents covering ubiquitin, SUMO, ISG15, and NEDD8 variants, alongside custom synthesis services that produce tailored ubiquitinated conjugates not readily achievable through biological methods. These tools support pharmaceutical drug discovery, fundamental academic research, and structural biology studies targeting the ubiquitin-proteasome system.

Differentiator

Problem solved

Functional benefit

Products and services

  • Catalogue Ubiquitin and Ubiquitin-Like Reagents Standardized catalogue of ubiquitinated peptides, activity-based probes, and activity assay reagents for ubiquitin and ubiquitin-like research, available for direct purchase. Products are manufactured at UbiQ's Amsterdam Science Park laboratory and are for laboratory research use only.
  • Custom Ubiquitin Reagents Service Custom chemical synthesis of tailored ubiquitinated conjugates and reagents for researchers with specific requirements not met by catalogue products, using UbiQ's site-selective chemical synthesis technology.
  • Custom Ubiquitinated Peptides Custom chemical synthesis of specific ubiquitinated peptides enabling researchers to design unique conjugates for specialized experimental needs, leveraging site-selective synthesis not achievable through biological approaches.
  • UbiQ-378 - Biotin-Ahx-Ub-MTC Activity-Based Probe Biotin-Ahx-Ub-MTC, a new type of activity-based probe for deubiquitinating enzymes, designed for researchers studying DUB activity and ubiquitin pathway mechanisms.
  • UbiQ-381 - L17ER4 Endosomolytic Peptide L17ER4, an endosomolytic peptide reagent for intracellular delivery of ubiquitin and ubiquitin-like reagents into live cells, enabling intracellular research applications.
  • UbiQ-344 - Ubiquitin (1-75) Ubiquitin(1-75) reagent prepared by total chemical synthesis, lacking the C-terminal Gly76 residue and therefore unable to be activated by an E1 enzyme, useful for specialized research applications.
  • UbiQ-158 - His6-3C-MAP1LC3a-Dha Activity-Based Probe His6-3C-MAP1LC3a-Dha, an activity-based probe targeting E1-E2-E3 enzymes involved in autophagy, designed for researchers studying autophagy-related enzyme mechanisms.

Quantifiable outcome

  • Tools used by many leading laboratories in the ubiquitin field worldwide
  • +1 more outcomes

Companies that use UbiQ

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

UbiQ technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

UbiQ partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core.

  • New York University School of MedicinecoreStrategic or Co-development Partner · 26 November 2025Collaborative research partnership with Tony T. Huang's lab at NYU School of Medicine on deubiquitinases regulating cleavage and stability of ubiquitin-fused ribosomal proteins, resulting in publication in Molecular Cell 2025.
  • Netherlands Cancer InstitutecoreStrategic or Co-development Partner · 1 August 2025Scientific collaboration with Niels Keijzer and team at NKI on USP1/UAF1 targeting polyubiquitinated PCNA, resulting in Nature Communications publication 2025.
  • Wroclaw University of Science and TechnologycoreStrategic or Co-development Partner · 16 January 2023Collaborative partnership contributing chapter to Methods in Molecular Biology book series on ubiquitin and ISG15 deconjugase characterization.
  • University of Texas Health Science CentercoreStrategic or Co-development Partner · 23 August 2022Collaborative research partnership contributing to characterization of SARS-CoV-1 and SARS-CoV-2 papain-like protease ubiquitin and ISG15 deconjugase activity, published in Methods in Molecular Biology 2023.
  • University of YorkcoreStrategic or Co-development Partner · 29 March 2022Collaborative research on essential roles of ubiquitin proteases and ubiquitin conjugation in Leishmania parasites with Prof Jeremy Mottram's lab.
  • University of GlasgowcoreStrategic or Co-development Partner · 29 March 2022Collaboration with Daniel Harris and Dr Richard Burchmore on ubiquitin activating enzyme as novel therapeutic target for leishmaniasis.
  • Beatson Institute for Cancer ResearchcoreStrategic or Co-development Partner · 29 March 2022Collaboration with Dr Danny Huang and Dr Mads Gabrielson on Leishmania ubiquitin system research.
  • University of LeedscoreStrategic or Co-development Partner · 29 May 2019International collaboration led by Dr Elton Zeqiraj on cryo-EM structure of human BRISC-SHMT2 complex involved in cell metabolism and immune response, published in Nature 2019.
  • University of PennsylvaniacoreStrategic or Co-development Partner · 29 May 2019Collaboration with Prof Roger Greenberg on structure of BRISC-SHMT2 complex showing metabolic regulation of immune signaling through ubiquitin pathway, published in Nature 2019.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

UbiQ competitors and assessment

Company assessment

Direct peers

  • LifeSensors: LifeSensors is the closest direct competitor to UbiQ. It specializes in ubiquitin, ubiquitin-like, and SUMO research reagents, activity-based probes, and enzymes, serving both academic and pharma drug-discovery customers in the UPS field.
  • UBPBio: UBPBio offers ubiquitin pathway research tools including DUB activity assays, ubiquitin chains, and E3 ligase substrates. It competes head-to-head with UbiQ in catalog DUB/UPS reagents used for compound screening and target validation.

Broad incumbents

  • MilliporeSigma (Merck KGaA Life Science): MilliporeSigma supplies an extensive catalog of biochemicals, proteins, and research reagents, including ubiquitin and proteasome-related products. As a global broad incumbent, it competes with UbiQ across standardized research reagents.
  • Promega Corporation: Promega provides a broad portfolio of life-science reagents and assay kits, including proteasome and protease tools. As a broad incumbent, it overlaps with UbiQ in drug-discovery assay reagents used by pharma and academic researchers.
  • Abcam: Abcam supplies research-grade antibodies and protein reagents, including products targeting ubiquitin pathway components. It competes with UbiQ in serving the same academic and pharma research customer base.
  • Cell Signaling Technology (CST): CST is a major provider of antibodies and reagents for cell signaling research, including UPS-related targets. It overlaps with UbiQ in serving academic and pharma labs studying post-translational modifications.
  • Enzo Life Sciences: Enzo supplies life-science research reagents including proteasome, DUB, and ubiquitin-related assay kits and inhibitors. It is a broad incumbent that overlaps with UbiQ in UPS drug-discovery tools.
  • Bio-Techne (R&D Systems / Tocris): Bio-Techne is a large life-science tools incumbent that supplies proteins, antibodies, and small-molecule reagents (including UPS-related tools) across pharma and academia. It competes broadly with UbiQ's reagent catalog and could enter adjacent ubiquitin specialties.

Emerging players

  • Cayman Chemical: Cayman Chemical supplies biochemical research tools including UPS-related probes, inhibitors, and assay reagents. It overlaps with UbiQ in serving drug-discovery and academic customers targeting the ubiquitin pathway.
  • South Bay Bio: South Bay Bio offers ubiquitin and ubiquitin-like reagents and conjugates, including di-ubiquitin chains and activity probes. As a smaller specialty provider, it competes with UbiQ in the UPS reagent niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

UbiQ social profiles

Digital presence

UbiQ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UbiQ leadership team

Management profile

Number of profiles

Profiles2 records

UbiQ funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UbiQ M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UbiQ

What does UbiQ do?

UbiQ develops, manufactures, and commercializes ubiquitin and ubiquitin-like research reagents, including ubiquitinated peptides, activity-based probes, and activity assay reagents, using proprietary site-selective chemical synthesis technology at its Amsterdam Science Park laboratory. The company offers a catalogue of standardized reagents covering ubiquitin, SUMO, ISG15, and NEDD8 variants, alongside custom synthesis services that produce tailored ubiquitinated conjugates not readily achievable through biological methods. These tools support pharmaceutical drug discovery, fundamental academic research, and structural biology studies targeting the ubiquitin-proteasome system.

Is UbiQ a public or private company?

UbiQ is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was UbiQ founded?

UbiQ was founded in 2010. It employs 1 to 10 people.

Where is UbiQ based?

UbiQ is headquartered in Amsterdam, Netherlands, in the Europe region.

How does UbiQ make money?

Two revenue lines are on record. Catalogue reagent sales are the primary driver. The others are custom reagent synthesis.

Who are UbiQ's main competitors?

Direct peers on record are LifeSensors and UBPBio. Broad incumbents are MilliporeSigma (Merck KGaA Life Science), Promega Corporation, Abcam, Cell Signaling Technology (CST), Enzo Life Sciences and Bio-Techne (R&D Systems / Tocris). Emerging players are Cayman Chemical and South Bay Bio.

Does UbiQ have an API?

No public API is recorded for UbiQ.

What industry is UbiQ in?

UbiQ's product category is Life Science Research Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales